December 19, 2017 / 1:18 PM / in a year

BRIEF-VBI Vaccines Announces First Patient Dosing In Phase 3 Clinical Program For Sci-B-Vac Hepatitis B Vaccine

Dec 19 (Reuters) - Vbi Vaccines Inc:

* VBI VACCINES ANNOUNCES FIRST PATIENT DOSING IN PHASE 3 CLINICAL PROGRAM FOR SCI-B-VAC HEPATITIS B VACCINE

* VBI VACCINES SAYS HEADLINE DATA FROM THE 15-MONTH PHASE 3 PROGRAM EXPECTED IN Q2 2019

* VBI VACCINES SAYS 4,800 SUBJECTS EXPECTED TO ENROLL IN TRIAL ACROSS TWO PHASE 3 STUDIES, PROTECT AND CONSTANT

* VBI VACCINES SAYS EXPECT TO SUBMIT MARKETING AUTHORIZATION APPLICATIONS FOR SCI-B-VAC TO U.S., EUROPEAN, CANADIAN AUTHORITIES IN 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below